Market view
Stock chart
Coverage
Analyses on Psyrx BIO-Tech (3)
- March 25, 2026March 25, 2026
- Follow-up
PsyRx: How real the patent moat is before first human data
Before first human data, PsyRx’s patent moat rests mainly on legal priority and broad drafting rather than on substantively tested exclusivity around a defined clinical combination.
- Follow-up
PsyRx: What the 2026 financing will cost shareholders
PsyRx's 2026 financing is a necessary survival bridge, but it is priced like a rewrite of the equity layer. The cost to shareholders is not just 27.09% or 28.96%. It is a combination of immediate dilution, a long option tail, ratchet protection, and effective influence over the…
PsyRx in 2025: The Shell Was Cleaned Up, but the Real Test Is Financing the First Human Trial
PsyRx entered 2026 as a cleaner operating and accounting story, but still without revenue and with cash that does not cover 12 months. That means the equity story now depends less on the raw science narrative and more on whether the company can close financing and reach first-in…
Same sector
